A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.
Laura Q ChowRafael Santana-DavilaAustin PantelMara RothLeslie N AndersonAlan FailorRobert DootDavid MankoffPublished in: PloS one (2017)
ClinicalTrials.gov NCT01413113.
Keyphrases